Clinical Trials Logo

Indolent Lymphoma clinical trials

View clinical trials related to Indolent Lymphoma.

Filter by:

NCT ID: NCT00980395 Completed - Lymphoma Clinical Trials

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

VCR
Start date: July 7, 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with cladribine and rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with cladribine and rituximab works in treating patients with advanced mantle cell lymphoma or indolent lymphoma.

NCT ID: NCT00954005 Terminated - Indolent Lymphoma Clinical Trials

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

R-GO
Start date: January 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.

NCT ID: NCT00687778 Recruiting - Lung Cancer Clinical Trials

11C-Acetate PET/CT Non-FDG-Avid Tumors

Start date: May 2008
Phase: N/A
Study type: Observational

F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are various types of human malignancies, which are not taking FDG in access. In these cases FDG is not a sensitive tracer of imaging. In search for other tumor PET tracers, C11-Acetate has been shown recently in a few early studies to have a potential value in imaging of non-FDG-avid tumors. The purpose of the current study is to assess the role of 11C-acetate PET in various tumors, which often are not detected by 18F-FDG and were not widely assessed until now.